Obstructive hydrocephalus

Summary

Obstructive hydrocephalus (MONDO:0001896) is a disease and 3 clinical trials. A subtype of hydrocephalus — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 3

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	obstructive hydrocephalus
Mondo ID	MONDO:0001896
DOID	DOID:14159
ICD-10-CM	G91.1
NCIT	C116347
SNOMED CT	230746009
UMLS	C0549423
MedGen	108198
Is cancer (heuristic)	no

Also known as: non-communicating hydrocephalus

Disease family

This is a subtype of hydrocephalus. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › brain disorder › hydrocephalus › obstructive hydrocephalus

Related subtypes (6): communicating hydrocephalus, craniosynostosis-Dandy-Walker malformation-hydrocephalus syndrome, congenital hydrocephalus, megalencephaly-polymicrogyria-postaxial polydactyly-hydrocephalus syndrome, baker Vinters syndrome, palmer pagon syndrome

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 3.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01041950	PHASE2/PHASE3	COMPLETED	A Randomised Controlled Trial of Lumbar Drainage to Treat Communicating Hydrocephalus After Severe Intraventricular Hemorrhage
NCT06132139	Not specified	NOT_YET_RECRUITING	VisAR Augmented Reality Navigation of Ventriculostomy
NCT01675037	Not specified	TERMINATED	Hypothalamic-pituitary Effects After Endoscopic Third Ventriculostomy